West Pharmaceutical Services (WST) return on invested capital (ROIC)
West Pharmaceutical Services (WST) earned a return on invested capital of 18.8% in fiscal 2025 (the year ended December 31, 2025). That is 0.5 percentage points lower than the 19.3% of fiscal 2024. Figures as of 17 Nov 2026, 22:34 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Return on invested capital, fiscal 2025
- 18.8%
- Change on fiscal 2024
- −0.5 pts
- Highest on record
- 30.0%fiscal 2022
- Lowest on record
- 18.8%fiscal 2025
- Fiscal years on record
- 42022–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
West Pharmaceutical Services return on invested capital (ROIC), in more detail
Across the 4 fiscal years on record (2022–2025), the highest was 30.0% in fiscal 2022 and the lowest 18.8% in fiscal 2025. The fiscal 2025 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is 25.0%.
Return on invested capital by fiscal year
West Pharmaceutical Services return on invested capital (ROIC), year by year
| Fiscal year | Return on invested capital | Change | Year ended |
|---|---|---|---|
| 2025 | 18.8% | 0.5 pts down | |
| 2024 | 19.3% | 5.7 pts down | |
| 2023 | 25.0% | 5.0 pts down | |
| 2022 | 30.0% | — |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.
How to read it
It measures how well the business turns capital into profit whoever supplied it; a figure above the cost of that capital, roughly 8–10%, means growth creates value.
Return on invested capital at health care companies of similar size
| Company | Return on invested capital | Fiscal year |
|---|---|---|
| Labcorp Holdings LH | 8.2% | 2025 |
| DexCom DXCM | 21.8% | 2025 |
| Koninklijke Philips PHG | 6.9% | 2025 |
| Roivant Sciences ROIV | -296.1% | 2026 |
| West Pharmaceutical Services WST | 18.8% | 2025 |
| Quest Diagnostics DGX | 8.9% | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
West Pharmaceutical Services, figure by figure
- West Pharmaceutical Services market cap
- West Pharmaceutical Services revenue
- West Pharmaceutical Services earnings
- West Pharmaceutical Services earnings per share (EPS)
- West Pharmaceutical Services P/E ratio
- West Pharmaceutical Services P/S ratio
- West Pharmaceutical Services P/B ratio
- West Pharmaceutical Services free cash flow
- West Pharmaceutical Services operating margin
- West Pharmaceutical Services dividend
- West Pharmaceutical Services shares outstanding
- West Pharmaceutical Services total debt
- West Pharmaceutical Services cash on hand
- West Pharmaceutical Services total assets
- West Pharmaceutical Services return on equity (ROE)
West Pharmaceutical Services (WST) overview: price, valuation and scorecardAll health care companies by market value
West Pharmaceutical Services return on invested capital (ROIC): questions and answers
What is West Pharmaceutical Services's return on invested capital?
West Pharmaceutical Services (WST) earned a return on invested capital of 18.8% in fiscal 2025 (the year ended December 31, 2025). That is 0.5 percentage points lower than the 19.3% of fiscal 2024.
Is West Pharmaceutical Services's return on invested capital high or low compared with its own history?
The fiscal 2025 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is 25.0%.
What are the highest and lowest return on invested capital figures on record for West Pharmaceutical Services?
Across the 4 fiscal years on record (2022–2025), the highest was 30.0% in fiscal 2022 and the lowest 18.8% in fiscal 2025.
How is West Pharmaceutical Services's return on invested capital calculated?
Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.
Fiscal years are named for the calendar year they end in.
Learn: return on invested capital (ROIC)
All stocks guides →- Return on invested capital (ROIC) vs ROE and ROA
Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “West Pharmaceutical Services (WST) return on invested capital (ROIC)”, data as of 17 November 2026. https://funkfolio.com/stock/WST/roic
Underlying data: the company's filings with the SEC and Yahoo Finance.